A Phase II Clinical Study of Cadonilimab in Combination With Chemotherapy as First-Line Treatment for PD-L1 Negative Advanced Non-Small Cell Lung Cancer
Overview
- Phase
- Phase 2
- Intervention
- Cadonilimab
- Conditions
- NSCLC
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Enrollment
- 54
- Locations
- 2
- Primary Endpoint
- 1-year Progression-Free Survival (PFS) rate
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.
Detailed Description
LungCadX is a multi-center, open-label, single-arm, investigator initiated, phase Ⅱ study. Patients received cadonilimab (10 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin \[area under the curve (AUC) 5 mg/mL per min, IV\] and paclitaxel \[175 mg/m2, IV\] for squamous NSCLC, or carboplatin \[AUC 5 mg/mL per min, IV\] and pemetrexed \[500 mg/m2, IV\] for non-squamous NSCLC) for up to four cycles, followed by maintenance therapy with cadonilimab for squamous NSCLC, and intravenous cadonilimab plus pemetrexed for non-squamous NSCLC. The primary endpoint was 12-month PFS rate by investigator assessment per RECIST 1.1. Secondary endpoints included PFS, OS, ORR，DoR，DCR, and the safety. Exploratory objective was to assess blood/tumor/urine/faeces tissue for potential biomarkers study. Adverse events will be monitored throughout the trial and graded according to the CTCAE v5.0.
Investigators
Chunxia Su
Director of Clinical Research Center, Shanghai Pulmonary Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria
- •Written informed consent must be obtained before implementing any trial-related procedures;
- •Aged 18-80 years;
- •Expected survival of more than 3 months;
- •The investigator confirms the presence of at least one measurable lesion according to RECIST 1.1 criteria;
- •Wild-type EGFR/ALK;
- •Patients with locally advanced (stage IIIb/IIIc), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not eligible for curative surgery and cannot undergo definitive radiotherapy/chemotherapy, according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer;
- •PD-L1 expression in tumor tissue with Tumor Proportion Score (TPS) \< 1%;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- •No prior systemic anti-tumor treatment for advanced/metastatic disease; patients who have previously received platinum-based adjuvant chemotherapy/radiotherapy, neoadjuvant chemotherapy/radiotherapy, or curative radiotherapy for advanced disease and experienced disease progression more than 6 months after the last treatment can participate in this study;
- •Adequate hematologic function, defined as absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L, platelet count \>= 100 x 10\^9/L, hemoglobin \>= 90 g/L (without transfusion history within 7 days);
Exclusion Criteria
- •Currently participating in interventional clinical research treatment;
- •Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (such as CTLA-4, OX-40, CD137);
- •Received traditional Chinese medicine or immunomodulatory drugs (such as thymopeptide, interferon, interleukin, etc.) with anti-tumor indications within 2 weeks prior to the first dose;
- •Known allergy to the active ingredient or any excipients of Cadonilimab;
- •Active hemoptysis, active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or peritoneal metastasis requiring clinical intervention;
- •Uncontrolled pleural effusion/ascites clinically (patients who do not require drainage of effusion or whose effusion does not increase significantly for 3 days can be included);
- •Tumor compression of important organs (such as the esophagus) with accompanying symptoms, compression of the superior vena cava, or invasion of mediastinal large blood vessels, heart, etc.;
- •History of severe complications such as severe pulmonary or cardiac disease, with any arterial thrombosis, embolism, or ischemia occurring within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or any other serious thrombotic events within 3 months prior to enrollment (thrombotic events related to implanted venous infusion ports or catheters, or superficial vein thrombosis are not considered "serious" thrombotic events);
- •History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, or glomerulonephritis related to antiphospholipid syndrome; Patients with stable hypothyroidism on replacement therapy with thyroid hormones are eligible to participate in this study; Patients with controlled type 1 diabetes after receiving a stable insulin treatment regimen are eligible to participate in this study;
- •Received systemic corticosteroids (\> 10 mg/day of prednisone or equivalent) or other systemic immunosuppressive agents (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] drugs) within 2 weeks prior to randomization; Use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids is allowed;
Arms & Interventions
Trial group
Cadonilimab (10 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin \[area under the curve (AUC) 5 mg/mL per min, IV\] and paclitaxel \[175 mg/m2, IV\] for squamous NSCLC, or carboplatin \[AUC 5 mg/mL per min, IV\] and pemetrexed \[500 mg/m2, IV\] for non-squamous NSCLC) for up to four cycles, followed by maintenance therapy with cadonilimab for squamous NSCLC, and intravenous cadonilimab plus pemetrexed for non-squamous NSCLC
Intervention: Cadonilimab
Outcomes
Primary Outcomes
1-year Progression-Free Survival (PFS) rate
Time Frame: 1 year
The 1-year Progression-Free Survival (PFS) rate refers to the proportion of patients who are alive and without disease progression one year after starting treatment.
Secondary Outcomes
- Progression-free Survival(up to 60 months)
- Overall Survival(up to 100 months)
- objective response rate(up to 24 months)
- duration of response(up to 24 months)